Literature DB >> 21445921

Transplantation for liver failure in patients with sickle cell disease: challenging but feasible.

Monika Hurtova1, Dora Bachir, Ketty Lee, Julien Calderaro, Thomas Decaens, Michael D Kluger, Elie Serge Zafrani, Daniel Cherqui, Ariane Mallat, Frédéric Galactéros, Christophe Duvoux.   

Abstract

Sickle cell disease (SCD) frequently affects the liver; if acute liver failure (ALF) develops, the only potentially effective therapeutic option is liver transplantation (LT). Only 12 patients for whom LT was performed for SCD-related ALF have been described so far. We report a retrospective series of 6 adult patients with SCD (3 men and 3 women, median age = 40.1 years) who underwent emergency LT. The indication for LT was ALF complicating cirrhosis in 5 patients (hepatitis C/iron overload-induced cirrhosis in 3 and iron overload-induced cirrhosis in 2); one patient had autoimmune hepatitis. The median follow-up was 52.7 months (0.5-123 months). The 1-, 3-, 5-, and 10-year survival rates were 83.3%, 66.7%, 44.4%, and 44.4%, respectively. One patient died of hepatocellular failure precipitated by hyperacute allograft rejection on post-LT day 10. Soon after LT, 2 patients developed seizures; in 1 case, the seizures were a complication of early calcineurin inhibitor-induced leukoencephalopathy. Four long-term survivors benefited from specific management of SCD; specifically, the hemoglobin S fraction was maintained below 30% and the total hemoglobin level was maintained between 8 and 10 g/dL. Two patients had mild vaso-occlusive crises. Three patients experienced a recurrence of hepatitis C virus (HCV) infection; 2 of these patients experienced reversible neurological complications while they were receiving antiviral treatment. Carefully selected patients with SCD may benefit from emergency LT. However, such patients seem to be particularly susceptible to neurological complications after LT. In contrast, severe SCD-related crises do not seem to recur if specific management is provided. Outcomes may be improved if the neurological complications can be minimized; for example, the administration of a calcineurin inhibitor can be delayed, and the management of HCV infection recurrence can be improved.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21445921     DOI: 10.1002/lt.22257

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  16 in total

Review 1.  Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease.

Authors:  Hitomi Hosoya; Jeffrey Levine; Peter Abt; David Henry; David L Porter; Saar Gill
Journal:  Blood Adv       Date:  2018-03-13

Review 2.  Management of liver complications in sickle cell disease.

Authors:  Abid R Suddle
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  Acute on chronic liver failure in a patient with sickle cell anaemia (HbSS).

Authors:  Dana DaEun Im; Utibe Essien; Jacqueline W DePasse; Victor Chiappa
Journal:  BMJ Case Rep       Date:  2015-07-01

4.  Liver stiffness increases acutely during sickle cell vaso-occlusive crisis.

Authors:  Christopher Koh; Tiffany Turner; Xiongce Zhao; Caterina P Minniti; Jordan J Feld; Jennifer Simpson; Mary Demino; Anna K Conrey; Mary J Jackson; Catherine Seamon; David E Kleiner; Gregory J Kato; Theo Heller
Journal:  Am J Hematol       Date:  2013-08-01       Impact factor: 10.047

Review 5.  Liver transplantation in alcoholic liver disease current status and controversies.

Authors:  Ashwani K Singal; Khushdeep S Chaha; Khalid Rasheed; Bhupinderjit S Anand
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

6.  First successful lung transplantation for sickle cell disease with severe pulmonary arterial hypertension and pulmonary veno-occlusive disease.

Authors:  M Patricia George; Enrico M Novelli; Norihisa Shigemura; Marc A Simon; Brian Feingold; Lakshmanan Krishnamurti; Matthew R Morrell; Cynthia G Gries; Syed Haider; Bruce A Johnson; Maria M Crespo; Jay K Bhama; Christian Bermudez; Samuel A Yousem; Yoshiya Toyoda; Hunter C Champion; Joseph M Pilewski; Mark T Gladwin
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

Review 7.  Clinical management of sickle cell liver disease in children and young adults.

Authors:  Eirini Kyrana; David Rees; Florence Lacaille; Emer Fitzpatrick; Mark Davenport; Nigel Heaton; Sue Height; Marianne Samyn; Fulvio Mavilio; Valentine Brousse; Abid Suddle; Subarna Chakravorty; Anita Verma; Girish Gupte; Marki Velangi; Baba Inusa; Emma Drasar; Nedim Hadzic; Tassos Grammatikopoulos; Jonathan Hind; Maesha Deheragoda; Maria Sellars; Anil Dhawan
Journal:  Arch Dis Child       Date:  2020-11-11       Impact factor: 3.791

8.  Liver Transplantation in Patients with Sickle Cell Disease in the United States.

Authors:  Rachel Hogen; Michelle Kim; Yelim Lee; Mary Lo; Navpreet Kaur; Jeff Kahn; Shefali Chopra; Yasir Qazi; Ashraf Sedra; Jim Kim; Lauren O'Brien; Yuri Genyk; Linda Sher; Juliet Emamaullee
Journal:  J Surg Res       Date:  2020-06-12       Impact factor: 2.192

9.  Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease.

Authors:  Ravi Vats; Silvia Liu; Junjie Zhu; Dhanunjay Mukhi; Egemen Tutuncuoglu; Nayra Cardenes; Sucha Singh; Tomasz Brzoska; Karis Kosar; Mikhil Bamne; Jude Jonassaint; Adeola Adebayo Michael; Simon C Watkins; Cheryl Hillery; Xiaochao Ma; Kari Nejak-Bowen; Mauricio Rojas; Mark T Gladwin; Gregory J Kato; Sadeesh Ramakrishnan; Prithu Sundd; Satdarshan Pal Monga; Tirthadipa Pradhan-Sundd
Journal:  Hepatology       Date:  2020-11-13       Impact factor: 17.425

Review 10.  Sickle Hepatopathy.

Authors:  Dibya L Praharaj; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2020-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.